OrthoPediatrics stock hits 52-week low at $20.94

OrthoPediatrics Corp. (NASDAQ:KIDS) stock has reached a new 52-week low, touching down at $20.94, with a sharp 17% decline just last week. The company maintains strong liquidity with a current ratio of 6.98, and InvestingPro analysis indicates the stock is currently trading near Fair Value. This latest price point reflects a significant downturn for the company, which specializes in medical devices for pediatric orthopedics. Over the past year, OrthoPediatrics has seen its stock value decrease by 33.02%, despite achieving 37.65% revenue growth in the last twelve months. Investors are closely monitoring the company's performance, looking for signs of a turnaround or further indicators of market pressures that could influence the stock's trajectory in the coming months. With analyst price targets ranging from $26 to $50, InvestingPro subscribers can access 5 additional key insights and a comprehensive Pro Research Report for deeper analysis of KIDS stock's potential.

In other recent news, OrthoPediatrics Corporation reported its fourth-quarter 2024 earnings, revealing a revenue of $52.7 million, which exceeded expectations of $50.72 million. Despite the revenue beat, the company's earnings per share (EPS) fell short of forecasts, recording a loss of -$0.69 against the anticipated -$0.30. The company has reiterated its guidance for 2025, projecting revenue growth between 15%-18% and adjusted EBITDA ranging from $15 million to $17 million. Additionally, OrthoPediatrics launched the VerteGlide Spinal Growth Guidance System, designed for treating Early Onset Scoliosis, which recently received FDA clearance. Lake Street Capital Markets initiated coverage on the company with a Buy rating and a price target of $37.00, highlighting the company's strong potential for growth. Meanwhile, JMP analysts maintained a Market Outperform rating with a $50.00 price target, reflecting a positive outlook on the company's performance. On the other hand, Stifel analysts adjusted their price target for OrthoPediatrics to $32.00 from $40.00, while maintaining a Buy rating, citing positive sales drivers for the future. These developments indicate a dynamic period for OrthoPediatrics, with both product innovation and strategic financial outlooks shaping its trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.